Analysts Keep Buy Ratings on Fractyl Health (GUTS)

Core Insights - Fractyl Health, Inc. (NASDAQ:GUTS) is recognized as one of the 10 Best New Penny Stocks to Invest In, with a Buy rating and a price target of $8 reiterated by Canaccord Genuity [1][3] Business Overview - Fractyl Health, Inc. is a metabolic therapeutics company focused on innovative approaches to treat serious metabolic diseases such as obesity and type 2 diabetes (T2D) [6] Clinical Developments - The company discussed the Revita procedure and its clinical profile during meetings with analysts, highlighting the positive clinical data shared so far [2][3] - Positive six-month results from the open-label REVEAL-1 Cohort were announced, showing that patients who underwent the Revita procedure maintained stable body weight and glycemic control after stopping GLP-1 therapy [4][5] Commercial Opportunities - The discussions emphasized the commercial opportunities for Fractyl Health, supported by the positive clinical outcomes, which have instilled confidence among analysts [2][3]